July 8, 2021 07:10 AM EDTUpdated July 9, 07:51 AM

In pursuit of a blockbuster, Amgen and AstraZeneca score priority review for asthma drug tezepelumab

Amber Tong

Amgen and AstraZeneca are one big step closer to realizing their blockbuster dreams for tezepelumab after the FDA granted a priority review for the asthma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In pursuit of a blockbuster, Amgen and AstraZeneca score priority review for asthma drug tezepelumab

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

In pur­suit of a block­buster, Am­gen and As­traZeneca score pri­or­i­ty re­view for asth­ma drug teze­pelum­ab

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

In pursuit of a blockbuster, Amgen and AstraZeneca score priority review for asthma drug tezepelumab